secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2022-11-28T23:59:59+00:00
Accession:  0001193125-22-292953
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ikena Oncology nominates IK-595 as first RAS pathway candidate; IND targeted H2 2023
--------------------------------------------------------------------------------

- IK-595: MEK-RAF complex inhibitor traps MEK & RAF in inactive complex, aims to avoid resistance.
- Discontinuing IK-007 (EP4 antagonist) internal development; exploring strategic alternatives.
- Cash runway extended into 2025; does not include potential IK-175 opt-in fees from BMS.
- IK-930 TEAD inhibitor monotherapy initial clinical data expected H2 2023; osimertinib combo starts H1 2023.
- Preclinical differentiation data for IK-595 planned for H1 2023; RAS pathway implicated in >500K US cancer cases/yr.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000119312522292953/0001193125-22-292953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000119312522292953/d420821d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-292953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer